The exostosin glycosyltransferase 1/STAT3 axis is a driver of breast cancer aggressiveness
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The epithelial–mesenchymal transition (EMT) program is crucial for transforming carcinoma cells into a partially mesenchymal state, enhancing their chemoresistance, migration, and metastasis. This shift in cell state is tightly regulated by cellular mechanisms that are not yet fully characterized. One intriguing EMT aspect is the rewiring of the proteoglycan landscape, particularly the induction of heparan sulfate proteoglycan (HSPG) biosynthesis. This proteoglycan functions as a co-receptor that accelerates cancer-associated signaling pathways through its negatively-charged residues. However, the precise mechanisms through which EMT governs HSPG biosynthesis and its role in cancer cell plasticity remain elusive. Here, we identified exostosin glycosyltransferase 1 (EXT1), a central enzyme in HSPG biosynthesis, to be selectively upregulated in aggressive tumor subtypes and cancer cell lines, and to function as a key player in breast cancer aggressiveness. Notably, ectopic expression of EXT1 in epithelial cells is sufficient to induce HSPG levels and the expression of known mesenchymal markers, subsequently enhancing EMT features, including cell migration, invasion, and tumor formation. Additionally, EXT1 loss in MDA-MB-231 cells inhibits their aggressiveness-associated traits such as migration, chemoresistance, tumor formation, and metastasis. Our findings reveal that EXT1, through its role in HSPG biosynthesis, governs signal transducer and activator of transcription 3 (STAT3) signaling, a known regulator of cancer cell aggressiveness. Collectively, we present the EXT1/HSPG/STAT3 axis as a central regulator of cancer cell plasticity that directly links proteoglycan synthesis to oncogenic signaling pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1. EXT1 expression and heparan sulfate levels correlate with breast cancer aggressiveness. (A) HSPG levels are upregulated in mesenchymal cell lines. The indicated breast cancer–derived cell lines were subjected to FACS analysis using heparan sulfate-specific 10E4 antibody (Left). The HS median fluorescence intensity was calculated for the epithelial (E) and mesenchymal cell lines (M) (Right); each bar represents the mean ± SD for n = 3. The P-value was determined by Student’s t test. (B) HSPG levels are upregulated in NAMEC vs. HMLE cells. NAMEC is an HMLE-derived cell line that spontaneously acquired the mesenchymal state. The indicated HMLE and NAMEC cell lines were subjected to FACS analysis using the indicated 10E4 antibody (Left). The HS median fluorescence intensity was calculated for the epithelial and mesenchymal cell lines (Right); each bar represents the mean ± SD for n = 5. The P-value was determined by Student’s t test, (C) EXT1 demonstrated elevated expression in mesenchymal cells. Cancer cell lines were divided into epithelial (n = 378 cell lines) and mesenchymal (n = 150 cell lines) groups based on the expression of known mesenchymal markers. The expression of the 10 HS biosynthesis genes was compared with the mean expression in each group. The regression line is presented as a dashed line. (D) The EXT1 protein level is upregulated in mesenchymal breast cancer cell lines. Cells were lysed and subjected to immunoblotting using the indicated antibodies. (E) EXT1 expression is upregulated during the EMT program. HMLE-Twist-ER cells were treated with 4-hydroxytamoxifen (OHT) to induce EMT for 15 d. The cells were collected every 3 d, then lysed and subjected to immunoblotting using the indicated antibodies. N-NAMEC cells. (F) TGFβ1 induces EXT1 expression. HCC1806 cells were treated with 5 ng/mL of TGFβ1 to induce the EMT program for 15 d. Cells were collected and subjected to immunoblotting on each indicated day using the indicated antibodies. (G) EXT1 expression in breast cancer patients correlates with the hallmark of EMT. Breast cancer patients’ gene expression data were generated by the TCGA (PanCancer Atlas project) and analyzed using the cBioPortal web tool (https://www.cbioportal.org). In these samples, the expression of EXT1 was compared to the whole transcriptome (~20,000 genes). The genes were then ranked based on the obtained Spearman’s rank correlation coefficient followed and subjected to gene set enrichment analysis (GSEA). GSEA computed the normalized enrichment score (NES) and false discovery rate (FDR) values. (H) EXT1 expression is elevated in the aggressive breast cancer subtypes. Breast cancer samples were divided into groups based on high and low EXT1 expression (one SD above or below the mean). For each group, the percentage of breast cancer subtypes is color-coded. The breast cancer data was obtained from the METABRIC databases. The cBioPortal calculated the P-values. Lum = luminal. (I) A table reporting the number of human breast cancer samples with “weak,” “moderate,” and “strong” EXT1 staining from triple-negative breast cancer (TNBC) or HER2+, PR-, and ER- (HER2+). Representative staining intensities are shown in images. Magnification, 20×, *P = 0.03 as determined by Fischer’s exact test. (J) EXT1 expression is associated with overall survival (OE), relapse-free survival (RFS), and DM-free survival (DMFS). Kaplan–Meier survival plots for patients with breast cancer were divided into high EXT1 expression [“high” (red)] and low [“low” (black)]. The numbers in parentheses indicate the total number of patients. These plots were generated by the Kaplan–Meier plotter website. The EXT1 (201995_at Affymetrix ID symbol) was used for all the analyses. The number of patients in each study is indicated in parentheses. The hazard ratio (HR) and the log-rank P-value (p) were determined by the analysis tool.](https://figures.cochat.ai/paper-figures/48f616d2a91b4002a133e76b6748fe49/the-exostosin-glycosyltransferase-1-stat3-axis-is-a-driver-of-breast-cancer-figure-1.jpg)





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When EMT is induced, Snail, ZEB, and Twist repress epithelial gene expression and induce mesenchymal genes ' expression such as EXT1 [35, 36].”
From Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer (2024) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 8×
“GENI performed a Spearman’s rank correlation coefficient analysis between EXT1 expression and the whole transcriptome ( ~ 20,000 genes) of 25 cancer types, followed by gene set enrichment analysis (GSEA) (35).”
MethodInfluentialIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · cited 1×
“By analyzing two databases available on the cBioPortal (36), namely the cancer genome atlas (TCGA, PanCancer Atlas project) (37) and the molecular taxonomy of breast cancer international consortium (METABRIC) (38), we found that EXT1 expression is significantly elevated in HER2 and basal compared…”
MethodclusterProfiler 4.0: A universal enrichment tool for interpreting omics data
(2021) · doi:10.1016/j.xinn.2021.100141 · Cited by 12,455
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672 · cited 1×
“We identified that in HMLE cells expressing Twist Family BHLH Transcription Factor 1 (Twist1) conjugated to estrogen receptor (HMLE - Twist - ER) (31), 4 - hydroxytamoxifen (4 - OHT) treatment for 15 d, upregulated EXT1 expression as well as other known mesenchymal markers such as vimentin (VIM)…”
BackgroundThe genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097 · cited 4×
“By analyzing two databases available on the cBioPortal (36), namely the cancer genome atlas (TCGA, PanCancer Atlas project) (37) and the molecular taxonomy of breast cancer international consortium (METABRIC) (38), we found that EXT1 expression is significantly elevated in HER2 and basal compared to luminal A samples…”
BackgroundInfluentialGyörffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., & Weinberg, R. A. (2004) · Cell · doi:10.1016/j.cell.2004.06.006 · Cited by 3,855 · cited 1×
“To rule out any cell - line–specific effects, we stained the immortalized human mammary epithelial (HMLE) cells (26) and their naturally occurring mesenchymal - derived cells (NAMEC) (27) with 10E4.”
BackgroundEMT Transition States during Tumor Progression and Metastasis
Pastushenko, I., & Blanpain, C. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.12.001 · Cited by 2,876
Hoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.022 · Cited by 2,546 · cited 1×
“To whether there is a clinical connection between EXT1 and STAT3 signaling, we analyzed TCGA pan - cancer data (44) and tumor microarrays. we found a significant association between EXT1 expression and IL - 6/JAK/STAT3 signaling ( SI Appendix , Fig.”
BackgroundComprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Ciriello, G., Gatza, M. L., Beck, A. H., Wilkerson, M. D., Rhie, S. K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.033 · Cited by 1,858 · cited 1×
“By analyzing two databases available on the cBioPortal (36), namely the cancer genome atlas (TCGA, PanCancer Atlas project) (37) and the molecular taxonomy of breast cancer international consortium (METABRIC) (38), we found that EXT1 expression is significantly elevated in HER2 and basal compared…”
Method
Cited by
Yoshimura, A., Horinaka, M., Yaoi, T., Ono, H., Itoh, K., Yamada, T., Takayama, K., & Sakai, T. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02727-2 · Cited by 15
The role of ncRNAs and exosomes in the development and progression of endometrial cancer
Niebora, J., Woźniak, S., Domagała, D., Data, K., Farzaneh, M., Zehtabi, M., Dari, M. A. G., Pour, F. K., Bryja, A., Kulus, M., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1418005 · Cited by 11
“Therefore, STAT3 has become a promising marker and potential therapeutic target in various types of cancers, such as lung, prostate, pancreatic, breast, and endometrial cancer (80 – 84).”
BackgroundGao, R., Lou, N., Yang, S., Yang, M., Fan, G., Dai, L., Tang, L. M., Yao, J., Han, X., & Shi, Y. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0993 · Cited by 11
Yuan, D., Xu, Y., Xue, L., et al. (2024) · Cell Biology International · doi:10.1002/cbin.12210 · Cited by 6
“Additionally, latest reports indicate that the STAT3 signaling axis plays a crucial role in EMT in tumor tissues (Das et al., 2023; Solaimuthu et al., 2024).”
Chen, H., Han, C., & Ha, C. (2024) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-024-05116-w · Cited by 3
“For example, Solaimuthu et al. point out that the expression of EXT1 is upregulated in breast cancer cells, inducing the expression of mesenchymal markers and enhancement of EMT features, which ultimately lead to cell migration, invasion, and tumor formation [13].”
Metadata
- Authors
- Solaimuthu, B., Khatib, A., Tanna, M., Karmi, A., Hayashi, A., Abu Rmaileh, A., Lichtenstein, M., Takoe, S., Jolly, M. K., & Shaul, Y. D.
- Affiliations
- Hebrew University of Jerusalem (IL)
- Department of Biochemistry and Molecular Biology, The Institute for Medical Research Israel-Canada, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112001, Israel
- Indian Institute of Science Education and Research Berhampur (IN)
- Indian Institute of Science Bangalore (IN)
- Corresponding author
- Shaul, Yoav David
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2024-01-12
- Volume
- 121
- Issue
- 3
- Pages
- e2316733121-e2316733121
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC10801894
- OpenAlex
- W4390819295
- Semantic Scholar
- c2566880672e24241a4e65093a85fe4da1e79d50
- Cited by
- 8
- References
- 66
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Funders
- Israel Science Foundation (299/21, 1816/16)
- Mizutani Foundation for Glycoscience (220087)
- HUJI | Lady Davis Fellowship Trust, Hebrew University of Jerusalem (0)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- EXT1, STAT3 signaling, epithelial-mesenchymal transition, breast cancer aggressiveness, tumor plasticity, chemoresistance, metastasis, cell migration and invasion, MDA-MB-231 cells
- MeSH terms
- Breast Neoplasms, Cell Line, Cell Movement, Female, Humans, Glycosyltransferases, Heparan Sulfate Proteoglycans, Cell Line, Tumor, STAT3 Transcription Factor, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The exostosin glycosyltransferase 1/STAT3 axis is a driver of breast cancer aggressiveness. https://app.cochat.ai/papers/10.1073/pnas.2316733121
- The paper
- Solaimuthu, B., Khatib, A., Tanna, M., Karmi, A., Hayashi, A., Abu Rmaileh, A., Lichtenstein, M., Takoe, S., Jolly, M. K., & Shaul, Y. D. (2024). The exostosin glycosyltransferase 1/STAT3 axis is a driver of breast cancer aggressiveness. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2316733121
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.